{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:51:38Z","timestamp":1783338698277,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1124\/dmd.108.024885","type":"journal-article","created":{"date-parts":[[2009,5,29]],"date-time":"2009-05-29T00:54:38Z","timestamp":1243558478000},"page":"1622-1634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to Rats"],"prefix":"10.1016","volume":"37","author":[{"given":"Y.","family":"Fukano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kawazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.108.024885_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5173(86)90124-9","article-title":"Permeability of prostaglandin F2\u03b1 and prostaglandin F2\u03b1 esters across cornea in vitro","volume":"29","author":"Camber","year":"1986","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.108.024885_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-5173(87)90006-8","article-title":"Factors influencing the corneal permeability of prostaglandin F2\u03b1 and its isopropyl ester in vitro","volume":"37","author":"Camber","year":"1987","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.108.024885_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0090-9556(25)06502-X","article-title":"Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits","volume":"23","author":"Higaki","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024885_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2006.00001.x","article-title":"Prostanoids in the therapy of glaucoma","volume":"24","author":"Ishida","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/dmd.108.024885_bib5","doi-asserted-by":"crossref","first-page":"5656","DOI":"10.1016\/S0021-9258(20)81155-7","article-title":"Carnitine-dependent \u03b2 oxidation of prostaglandins","volume":"247","author":"Johnson","year":"1972","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.108.024885_bib6","first-page":"387","article-title":"Aqueous humor dynamics: how PGF2\u03b1 lowers intraocular pressure","volume":"312","author":"Kaufman","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1124\/dmd.108.024885_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/jop.1998.14.389","article-title":"Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro","volume":"14","author":"Madhu","year":"1998","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.108.024885_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.tetlet.2003.12.029","article-title":"Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: a novel 15-deoxy-15,15-difluoroprostaglandin F2\u03b1 derivative","volume":"45","author":"Matsumura","year":"2004","journal-title":"Tetrahedr Lett"},{"key":"10.1124\/dmd.108.024885_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1248\/bpb.26.1691","article-title":"New fluoroprostaglandin F2\u03b1 derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents","volume":"26","author":"Nakajima","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.108.024885_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2\u03b1-1-isopropylester in the cynomolgus monkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp Eye Res"},{"key":"10.1124\/dmd.108.024885_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0378-5173(83)90041-8","article-title":"The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits","volume":"17","author":"Redell","year":"1983","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.108.024885_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcp.1030590106","article-title":"Comparative metabolism of tritiated water by mammals","volume":"59","author":"Richmond","year":"1962","journal-title":"J Cell Comp Physiol"},{"key":"10.1124\/dmd.108.024885_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/108076802760116205","article-title":"A retrospective review of non-responders to latanoprost","volume":"18","author":"Scherer","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.108.024885_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1211\/0022357991772989","article-title":"[3H]AL-5848 ([3H]9\u03b2-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor","volume":"51","author":"Sharif","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.108.024885_bib15","first-page":"745","article-title":"The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit","volume":"26","author":"Sj\u00f6quist","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024885_bib16","first-page":"234","article-title":"Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye","volume":"49","author":"Sj\u00f6quist","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/dmd.108.024885_bib17","first-page":"513","article-title":"Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2\u03b1 analogue","volume":"23","author":"Stjernschantz","year":"1995","journal-title":"Adv Prostaglandin Thromboxane Leukot Res"},{"key":"10.1124\/dmd.108.024885_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/jop.2006.0061","article-title":"A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males","volume":"23","author":"Sutton","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.108.024885_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","article-title":"Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug","volume":"78","author":"Takagi","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1124\/dmd.108.024885_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.1996.12.489","article-title":"Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits","volume":"12","author":"Taniguchi","year":"1996","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/dmd.108.024885_bib21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0090-9556(25)06670-X","article-title":"An improved HPLC assay for the assessment of liver slice metabolic viability using 7-ethoxycoumarin","volume":"23","author":"Walsh","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024885_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(98)91372-0","article-title":"Latanoprost. Two years\u2019 experience of its use in the United Kingdom. Latanoprost Study Group","volume":"105","author":"Watson","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1124\/dmd.108.024885_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198005010-00001","article-title":"Drug excretion in human breast milk","volume":"5","author":"Wilson","year":"1980","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.108.024885_bib24","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/S0039-6257(01)00224-7","article-title":"The pharmacology of bimatoprost (Lumigan)","volume":"45","author":"Woodward","year":"2001","journal-title":"Surv Ophthalmol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624021275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624021275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.108.024885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:40:23Z","timestamp":1739896823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624021275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0090955624021275"],"URL":"https:\/\/doi.org\/10.1124\/dmd.108.024885","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disposition and Metabolism of a Novel Prostanoid Antiglaucoma Medication, Tafluprost, Following Ocular Administration to Rats","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.108.024885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}